Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma-Reference-Cited by-同舟云学术

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma

Published:2008-08-01 Issue:3 Volume:113 Page:508-514
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ansell Stephen M.,Inwards David J.,Rowland Kendrith M.,Flynn Patrick J.,Morton Roscoe F.,Moore Dennis F.,Kaufmann Scott H.,Ghobrial Irene,Kurtin Paul J.,Maurer Matthew,Allmer Christine,Witzig Thomas E.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project;Blood.,1997

2. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies;Witzig;Curr Treat Options Oncol.,2006

3. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma;Witzig;J Clin Oncol.,2005

4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med.,2007

Cited by 193 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01

2. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study;Blood Cancer Journal;2023-11-13

3. A Comprehensive Review of Systemic Targeted Therapies in Cancer Treatment;Current Cancer Therapy Reviews;2023-10-25

4. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects;International Journal of Molecular Sciences;2023-09-14

5. Clinical Experiences with Drugs Targeting m TOR;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15